Table 1.

Selected studies of intensive therapy with BCR-ABL1 TKIs for Ph+ ALL

StudyRegimenNAge, median (range), yCR rate, %IM, %Overall survival
UKALLXII/E299335  Imatinib + chemotherapy 175 42 (16-64) 92 38% (4  y) 
MDACC36  Imatinib + HyperCVAD 70 51 (17-84) 93 43% (5  y) 
MDACC40  Dasatinib + HyperCVAD 72 55 (21-80) 96 52% (5  y) 
Korean28  Nilotinib + multiagent chemotherapy 90 47 (17-77) 91 72% (2  y) 
MDACC44  Ponatinib + HyperCVAD 86 46 (21-80) 100 78% (3  y) 
PONAFIL56  Ponatinib + chemotherapy 30 49 (19-59) 100 96% (3  y) 
StudyRegimenNAge, median (range), yCR rate, %IM, %Overall survival
UKALLXII/E299335  Imatinib + chemotherapy 175 42 (16-64) 92 38% (4  y) 
MDACC36  Imatinib + HyperCVAD 70 51 (17-84) 93 43% (5  y) 
MDACC40  Dasatinib + HyperCVAD 72 55 (21-80) 96 52% (5  y) 
Korean28  Nilotinib + multiagent chemotherapy 90 47 (17-77) 91 72% (2  y) 
MDACC44  Ponatinib + HyperCVAD 86 46 (21-80) 100 78% (3  y) 
PONAFIL56  Ponatinib + chemotherapy 30 49 (19-59) 100 96% (3  y) 

IM, induction mortality; MDACC, MD Anderson Cancer Center.